Sightsavers Logo
Research centre
  • Home
  • About us
  • Research approach
  • Research studies and publications
  • Evidence gap maps
Join in:
  • Join in: Facebook
  • Join in: Twitter
  • Join in: Instagram
  • Join in: LinkedIn
  • Join in: YouTube
  • Global
  • Close search bar
    Donate
    • Home
    • About us
    • Research approach
    • Research studies and publications
    • Evidence gap maps

    Conjunctival hyperemia with use of a fixed combination of latanoprost/timolol: a systematic review and meta-analysis of clinical trials

    Methodological quality of the review: Medium confidence

    Author: Vinuesa-Silva JM, Vinuesa-Silva I, Pinazo-Durán MD, Soto-Alvarez J, Delgado-Ortega L, Díaz-Cerezo S

    Geographical coverage: Not reported

    Sector: Glaucoma

    Sub-sector: Conjunctival hyperemia

    Equity focus: None specified

    Review type: Effectiveness review

    Quantitative synthesis method: Meta-analysis

    Qualitative synthesis method, if applicable: Not applicable

    Background: Glaucoma is one of the most prevalent causes of blindness worldwide. In patients with high intra-ocular pressure (IOP), treatments are based on the reduction of IOP to delay or prevent the progression of the disease. Topical treatments are the most commonly used medications. These drugs may result in local or systematic effects. Conjunctival hyperemia is the most common secondary effect of prostaglandins. Therefore, it is important to systematically assess the literature for this secondary effect.

    Objectives: To assess the association of conjunctival hyperemia with the use of a fixed combination of latanoprost/ timolol, through a systematic review and meta-analysis of clinical trials in patients with glaucoma.

    Main findings: In this systematic review, eight clinical trials remained for inclusion in the meta-analysis, all of which included patients with ocular hypertension or glaucoma and provided specific hyperemia data for a total of 2600 patients.

    There was a moderate heterogeneity (Q: 14.64; df=7; p=0.041; I2=52.2%) and therefore a random effects model was used. The final odds ratio (OR) was 0.47 (CI 95%: 0.24-0.90); p = 0.024. The total conjunctival hyperemia incidence was 2.9% in the latanoprost/timolol group and 7.0% for the competitors (p< 0.0001). The sensitivity analyses indicated that the mean aggregate OR could range between 0.39 and 0.50 depending on the clinical trial excluded of the meta-analysis. None had a significant impact in the global calculation of OR because in all cases the latanoprost/timolol exhibited a degree of hyperemia significantly lower than the comparator group. No bias was found within included studies.

    Authors concluded that, compared with other options for the treatment of glaucoma, a fixed combination of latanoprost/timolol is associated with a significant reduction in the development of conjunctival hyperemia. A fixed combination of latanoprost/timolol has the lowest side effects compared with other medications

    It was also noted that future studies should include a greater number of trials and search for a longer period of time.

    Methodology: The following databases were used in the search for published relevant articles: MEDLINE, EMBASE and Cochrane Controlled Clinical Trials Register between 2000 and 2007. Relevant papers were selected by two independent researchers according to the following criteria:

    (a) Comparative clinical trials (excluding crossed designs)

    (b) Existence of an active control in the trial

    (c) Assessment of the prevalence of conjunctival hyperemia due to treatments

    Two authors carried out the extraction of data using a codification sheet. In addition, they evaluated the methodological quality of included studies using the Jadad scale. However, it’s not clear if this was done independently.

    Meta-analysis was carried out with the programme Comprehensive Meta-Analysis version 2.2. OR of the various clinical trials were combined using a fixed-effect model of Mantel-Haenszel for homogeneous trials, and the random effect model of Der Simonian and Laird (for heterogeneous clinical trials). Heterogeneity between trials was analysed using Q for Cochrane test and the index /2 calculation which allowed the authors to determine the way in which possible existing heterogeneity could affect the conclusions of the meta-analysis. Publication bias was assessed with the visual inspection of the funnel plot. Sensitivity analysis was conducted to assess the robustness of the results.

    Applicability/external validity: The authors did not discuss the applicability/external validity of the results.

    Geographic focus: The authors failed to highlight or mention the geographical focus of the review.

    Summary of quality assessment: Overall, there is medium confidence in the conclusions about the effects of this study. Authors conducted a search of the literature on relevant databases without any publication type or language restrictions, but restricted the search for studies published between 2000 and 2007.

    However, authors did not contact authors/experts and did not check reference lists to ensure that all relevant published and unpublished studies were identified. As such, publication bias should not be excluded from the review. Authors used appropriate methods to select studies for inclusion in the review and to extract data of included studies, minimising bias. Methods used to analyse data of included studies were also appropriate and limitations were acknowledged accordingly.

    Publication source: Vinuesa-Silva JM, Vinuesa-Silva I, Pinazo-Durán MD, Soto-Alvarez J, Delgado-Ortega L, Díaz-Cerezo S. Conjunctival hyperemia with use of a fixed combination of latanoprost/timolol: systematic review and meta-analysis of clinical trials. Arch Soc Esp Oftalmol. 2009 Apr;84(4):199-207. Source
    Sightsavers Logo
    Research centre
    • Join in:
    • Join in: Facebook
    • Join in: X
    • Join in: Instagram
    • Join in: LinkedIn
    • Join in: YouTube

    Protecting sight, fighting disease and promoting equality for all

  • Accessibility
  • Sightsavers homepage
  • Our policies
  • Media centre
  • Contact us
  • Jobs
  • Cookies and privacy Terms and conditions Modern slavery statement Safeguarding

    © 2025 by Sightsavers, Inc., Business Address for all correspondence: One Boston Place, Suite 2600, Boston, MA 02108.

    Our website uses cookies

    To make sure you have a great experience on our site, we’d like your consent to use cookies. These will collect anonymous statistics to personalise your experience.

    Manage preferences

    You have the option to enable non-essential cookies, which will help us enhance your experience and improve our website.

    Essential cookiesAlways on

    These enable our site to work correctly, for example by storing page settings. You can disable these by changing your browser settings, but some parts of our website will not work as expected.

    Analytics cookies

    To improve our website, we’d like to collect anonymous data about how you use the site, such as which pages you read, the device you’re using, and whether your visit includes a donation. This is completely anonymous, and is never used to profile individual visitors.

    Advertising cookies

    To raise awareness about our work, we’d like to show you Sightsavers adverts as you browse the web. By accepting these cookies, our advertising partners may use anonymous information to show you our adverts on other websites you visit. If you do not enable advertising cookies, you will still see adverts on other websites, but they may be less relevant to you. For info, see the Google Ads privacy policy.